Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614577 Target Snapshot

LLC-PK1 · CELL-LINE · Sus scrofa

Back to Search Search this target Browse approvals Evidence Card
1,219Compounds
424Assays
1Approved Drugs
129.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats LLC-PK1 as ChEMBL target CHEMBL614577. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
LLC-PK1
CELL-LINE · Sus scrofa
As of 2026-09-14
ChEMBL target ID
CHEMBL614577
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether LLC-PK1 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLLC-PK1
Target TypeCELL-LINE
OrganismSus scrofa
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLLC-PK1
UniProt AccessionN/A

LLC-PK1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as LLC-PK1.

Review nameLLC-PK1
OrganismSus scrofa
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50129.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL497451 9.19 IC50 0.65 Preclinical
CHEMBL499036 7.71 IC50 19.43 Preclinical
CHEMBL53463 6.7 IC50 200.0 Approved
CHEMBL1915706 5.54 IC50 2890.0 Preclinical
CHEMBL504574 5.4 IC50 3990.0 Preclinical
CHEMBL1915697 5.35 IC50 4460.0 Preclinical
CHEMBL2259872 5.24 IC50 5800.0 Preclinical
CHEMBL1172104 5.22 IC50 6000.0 Preclinical
CHEMBL2260081 5.17 IC50 6800.0 Preclinical
CHEMBL3358767 5.02 IC50 9620.0 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
3
5.5
1
6.0
1
6.5
0
7.0
1
7.5
0
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
Assay Landscape

Assay Landscape

429
Total Assays
28
Tested Compounds
4
Assay Types
ADME — 334 assays, 28 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 334 28 4.9
Functional — 92 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 92 2 8.4
Toxicity — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine